Thrombomodulin Levels during Normal Pregnancy, at Delivery and in the Postpartum: Comparison with Tissue-type Plasminogen Activator and Plasminogen Activator Inhibitor-1

Summary

Some studies suggest that soluble thrombomodulin (TM) could be used as a marker of preeclampsia or eclampsia. However little is known about the sequential changes of TM during the course of normal pregnancy.

Levels of TM were determined in 100 women with uneventful pregnancies. Samples (n = 394) were divided into five study intervals, three during pregnancy, one at delivery and one three days postpartum.

As compared with TM levels (median 34.3 ng/ml, range 17.6-61) of a control group of 60 healthy non-pregnant women, TM levels were shown to increase throughout pregnancy, median (and range) values being respectively 38.5 (17.6-72.7) from 11 to 20 weeks, 45.2 (22.6-75.2) from 21 to 30 weeks and 54.3 (25.1-114.5) ng/ml from 31st week to delivery. One hour after delivery TM levels were still elevated and dropped three days postpartum to 40.5 (20.9-79.4) ng/ml. The increase of TM levels was correlated with those of tissue-type plasminogen activator and plasminogen activator inhibitor-1 antigens. The large overlap in TM levels between the study periods seems to preclude a clinical use of TM based on reference values from a control group. Our data suggest that it would be more appropriate to take into account TM baseline values in a given woman to examine her TM increase during pregnancy.

• References

• 1 Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-6.
• 2 Ishii H, Majerus PW. Thrombomodulin is present in plasma and urine. J Clin Invest 1985; 76: 2178-81.
• 3 Boffa M-C. Considering cellular thrombomodulin distribution and its modulating factors can falicitate the use of plasma thrombomodulin as a reliable endothelial marker. Haemostasis 1996; Suppl (04) 233-43.
• 4 Minakami H, Takahashi T, Izumi A, Tamada T. Increased levels of plasma thrombomodulin in preeclampsia. Gynecol Obstet Invest 1993; 36: 208-10.
• 5 Hsu C-D, Copel J, Hong S-F, Chan DW. Thrombomodulin levels in preeclampsia, gestational hypertension, and chronic hypertension. Obstet Gynecol 1995; 86: 897-9.
• 6 Bontis J, Vavilis D, Agoratos T, Zournatzi V, Konstantinidis T, Tagou K. Maternal plasma level of thrombomodulin is increased in mild preeclampsia. Eur J Obstet Gynecol 1995; 60: 139-41.
• 7 Shaarawy M, El Didy H. Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia. Int J Gynecol Obstet 1996; 55: 135-9.
• 8 Hellgern M, Blombäck M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. Gynecol Obstet Invest 1981; 12: 141-54.
• 9 Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in pregnancy. Thromb Haemost 1984; 52: 176-82.
• 10 Kruithof EKO, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H, Bachmann F. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987; 69: 460-6.
• 11 Mackinnon S, Walker ID, Davidson JF, Walker JJ. Plasma fibrinolysis during and after normal childbirth. Br J Haematol 1987; 65: 339-42.
• 12 Estelles A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe pre-eclampsia. Blood 1989; 74: 1332-8.
• 13 Bonnar J, Daly L, Sheppard BL. Changes in the fibrinolytic system during pregnancy. Semin Thromb Haemostas 1990; 16: 221-9.
• 14 van Wersh JW, Ubachs JM. Blood coagulation and fibrinolysis during pregnancy. Eur J Clin Chem Clin Biochem 1991; 29: 45-50.
• 15 Bremme K, Ostlund E, Almqvist I, Heinonen K, Blombäck M. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium. Obstet Gynecol 1992; 80: 132-7.
• 16 Reith A, Booth N, Moore NR, Cruickshank DJ, Bennett B. Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, preeclampsia and hydatidiform mole. Br J Obstet Gynecol 1993; 100: 370-4.
• 17 Halligan A, Bonnar J, Sheppard B, Darling M, Walshe J. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia. Br J Obstet Gynecol 1994; 101: 488-92.
• 18 Sorensen JD, Secher NJ, Jespersen J. Perturbed (procoagulant) endothelium and deviations within the fibrinolytic system during the third trimester of normal pregnancy. Acta Obstet Gynecol Scand 1995; 74: 257-61.
• 19 Amiral J, Adam M, Mimilia F, Larrivaz I, Chambrette B, Boffa MC. Design and validation of a new immunoassay for soluble forms of thrombomodulin and studies in plasma. Hybridoma 1994; 13: 205-13.
• 20 Ballegeer V, Mombaerts P, Declerck PJ, Spitz B, Van Assche FA, Collen D. Fibrinolytic response to venous occlusion and fibrin fragment D-dimer levels in normal and complicated pregnancy. Thromb Haemost 1987; 58: 1030-2.
• 21 Cadroy Y, Grandjean H, Pichon J, Desprats R, Berrebi A, Fournié A, Boneu B. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynecol 1993; 100: 416-20.
• 22 Wright JG, Cooper P, Astedt B, Lecander I, Wilde JT, Preston FE, Greaves M. Fibrinolysis during normal human pregnancy: complex interrelationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time. Br J Haematol 1988; 69: 253-8.